Nature Communications (Sep 2023)

Deleterious heteroplasmic mitochondrial mutations are associated with an increased risk of overall and cancer-specific mortality

  • Yun Soo Hong,
  • Stephanie L. Battle,
  • Wen Shi,
  • Daniela Puiu,
  • Vamsee Pillalamarri,
  • Jiaqi Xie,
  • Nathan Pankratz,
  • Nicole J. Lake,
  • Monkol Lek,
  • Jerome I. Rotter,
  • Stephen S. Rich,
  • Charles Kooperberg,
  • Alex P. Reiner,
  • Paul L. Auer,
  • Nancy Heard-Costa,
  • Chunyu Liu,
  • Meng Lai,
  • Joanne M. Murabito,
  • Daniel Levy,
  • Megan L. Grove,
  • Alvaro Alonso,
  • Richard Gibbs,
  • Shannon Dugan-Perez,
  • Lukasz P. Gondek,
  • Eliseo Guallar,
  • Dan E. Arking

DOI
https://doi.org/10.1038/s41467-023-41785-7
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 16

Abstract

Read online

Abstract Mitochondria carry their own circular genome and disruption of the mitochondrial genome is associated with various aging-related diseases. Unlike the nuclear genome, mitochondrial DNA (mtDNA) can be present at 1000 s to 10,000 s copies in somatic cells and variants may exist in a state of heteroplasmy, where only a fraction of the DNA molecules harbors a particular variant. We quantify mtDNA heteroplasmy in 194,871 participants in the UK Biobank and find that heteroplasmy is associated with a 1.5-fold increased risk of all-cause mortality. Additionally, we functionally characterize mtDNA single nucleotide variants (SNVs) using a constraint-based score, mitochondrial local constraint score sum (MSS) and find it associated with all-cause mortality, and with the prevalence and incidence of cancer and cancer-related mortality, particularly leukemia. These results indicate that mitochondria may have a functional role in certain cancers, and mitochondrial heteroplasmic SNVs may serve as a prognostic marker for cancer, especially for leukemia.